Research Article

MicroRNA-139-5p Suppresses Cell Malignant Behaviors in Breast Cancer through Targeting MEX3A

Jian Chu,1,2 Tangya Li,1,2 Lei Li,1,2 and Huiwen Fan1,2

1Department of General Surgery, The First People’s Hospital of Yancheng, Yancheng, 224005 Jiangsu Province, China
2Yancheng First Hospital, Affiliated Hospital of Nanjing University Medical School, China

Correspondence should be addressed to Huiwen Fan; fhw_83@163.com

Received 9 September 2021; Revised 9 October 2021; Accepted 12 October 2021; Published 2 November 2021

Objective. The study was designed to evaluate the underlying mechanism of microRNA-139-5p in breast cancer (BC).

Methods. Expression statuses of microRNA-139-5p and MEX3A were measured by qRT-PCR and western blotting. The anticancer effect of microRNA-139-5p in vitro was tested by a set of assays. Interaction between microRNA-139-5p and MEX3A was validated by dual-luciferase detection.

Results. MicroRNA-139-5p expression in BC cells was obviously low, while MEX3A was significantly overexpressed. MicroRNA-139-5p restrained proliferative, invasive, and migratory abilities of BC cells and increased apoptosis level of BC cells, while MEX3A exerted a promoting effect on BC cell growth. Dual-luciferase reporter detection confirmed that microRNA-139-5p bound to MEX3A 3′-UTR.

Conclusions. MicroRNA-139-5p inhibited the development of BC by targeting MEX3A. MicroRNA-139-5p/MEX3A may be a target for BC therapy.

1. Introduction

Breast cancer (BC), which is commonly diagnosed in women, gives rise to the second frequent cancer-related death [1]. In 2018, up to 2.1 million women were diagnosed with BC [2]. The 5-year survival rate of BC patients has been improved, but the 5-year survival rate of those patients with metastatic BC is just about 26% [3]. Because of the heterogeneity of BC metastasis, it is difficult to determine therapies and assess metastasis risk [4]. Therefore, focusing on molecular mechanism and therapies of occurrence and metastasis of BC may help to improve the survival rate of patients and offer new ideas for targeted therapy of BC.

MicroRNAs take part in physiological and pathological processes in the human body, like cell apoptosis, cell differentiation, and organ development, thus inhibiting or facilitating the occurrence of human cancer [5]. Many studies have demonstrated that various microRNAs regulate the occurrence and development of BC, such as microRNA-193a [4], microRNA-140-5p [6], and microRNA-1228 [7]. MicroRNA-139-5p has been shown to modulate the growth of cancer cells. Yang et al. [8] discovered that microRNA-139-5p facilitates prostate cancer progress by modulating SOX5 and significantly affects the prognosis of prostate cancer. In addition, Chen et al. [9] have reported that microRNA-139-5p is significantly downregulated in uterine leiomyoma tissues, and microRNA-139-5p blocks proliferation of uterine leiomyoma cells, as well as induces cell apoptosis via degenerating TPD52. Li et al. [10] demonstrated that microRNA-139-5p targeting Notch1 restrains metastasis and EMT in glioma. However, how microRNA-139-5p functions in BC needs further in-depth investigation.

MEX3 family participates in physiological processes such as immune response, metabolism, and cancer [11]. MEX3A is a new component in mammals containing GW-182 or Dcp that functions as a cellular site for mRNA degradation [12]. MEX3A has been confirmed to be significantly related to the occurrence of cancers, such as bladder cancer [13] and Wilms tumor [14]. However, the role of MEX3A in BC has less been studied.

In the current study, microRNA-139-5p expression and its biological functions in BC were analyzed. MicroRNA-139-5p and MEX3A interaction was also evaluated to reveal the effects of microRNA-139-5p on BC development. We
indicated an underlying role of microRNA-139-5p/MEX3A in BC process, which could be a theoretical support for novel therapeutical targets or biomarkers.

2. Materials and Methods

2.1. Bioinformatics Approaches. Expression data information of mature microRNAs (normal: 104, tumor: 1,103) and mRNAs (normal: 113, tumor: 1,109) of TCGA-BRCA was accessed from The Cancer Genome Atlas (TCGA) database. MicroRNA-139-5p expression was analyzed on basis of the downloaded data. R package “edgeR” was used to carry out differential expression analysis on mRNAs in TCGA-BRCA dataset with the normal group as the control and |logFC| >2, p adj < 0.01 as thresholds to acquire differentially expressed mRNAs (DEmRNAs). MicroRNA-139-5p target binding prediction was conducted by using targetScan, miRDB, and mirDIP databases, and the predicted mRNAs were intersected with upregulated DEmRNAs to screen the potential miR-139-5p targets. Correlation analysis was conducted to select miR-139-5p target mRNA presenting the highest negative correlation efficiency with miR-139-5p at expression level. Survival analysis of 11 target genes was processed by the GEPIA database.

2.2. Cell Cultivation. Human normal breast epithelial cell line MCF-10A (BNCC337734) and human BC cell lines MDA-MB-231 (BNCC337893), MCF7 (BNCC337656), HCC1937 (BNCC338509), and MX-1 (BNCC100280) were offered by BeNa Culture Collection (Beijing, China). MCF-10A, HCC1937, and MX-1 were grown in 90% RPMI-1640 (HyClone, USA) + 10% fetal bovine serum (FBS; Thermo Scientific HyClone, Beijing, China). MDA-MB-231 and MCF7 were cultivated in DMEM (Thermo, USA) with 10% FBS.

2.3. Transfection of Cells. MicroRNA-139-5p mimics, microRNA-139-5p inhibitor, oe-MEX3A, and corresponding negative controls were offered by GenePharma Company (Shanghai, P.R. China). Nontransfected control was presented to identify the transfection efficiency (Figure S1). 1.5 μL/mL Lipofectamine 2000 transfection reagent (ThermoFisher, USA) was utilized to get 50 nM gene segment or 1 μg plasmid transfected into BC cells. Experiments were carried out 24 h after cell culture, and transfection lasted for 48 h.

2.4. qRT-PCR. After total RNA was isolated by TRIzol reagent (ThermorFisher, USA), it was quantified using NanoDrop (ThermoFisher, USA). Reverse transcription of mRNAs and microRNA was performed by using the SuperScript III First-Strand Synthesis System kit (Invitrogen, USA) and NCode™ VILO™ microRNA cDNA Synthesis kit (Life Technologies). qRT-PCR analysis of mRNAs and microRNAs was conducted by using the SoFast™ EvaGreenH Supermix (Bio-Rad) and EXPRESS SYBR Green ER microRNA qRT-PCR kit (Life Technologies), respectively. U6 and GAPDH were used as internal control genes. The following were primer sequences: microRNA-139-5p forward: 5′-TCTACAGTGACGTCAGAGTGGCT-3′, reverse: 5′-GAATACCTCGGACCCGTG-3′; U6 forward: 5′-CTCG TTTGCGAACAATAATGAGAGC-3′, reverse: 5′-AACGATTCAGC AATTTCGCTG-3′; MEX3A forward: 5′-CGGAGTCGACT CTGGCCTTGGAG-3′, reverse: 5′-CACGGAGAAGGC ACAGGAGGT-3′; GAPDH forward: 5′-TGACTTCAACAG GACACCCA-3′, reverse: 5′-CACCCTGTTGCTGTA GCCAAA-3′. MicroRNA or mRNA relative expression was analyzed by the 2^ΔΔCt method.

2.5. Western Blotting. RIPA buffer solution (Solarbio, Beijing, China) was used to isolate total proteins in each group. The concentration of extracted samples was determined by the BCA assay kit (Abcam, Cambridge, UK). Separated by 10% SDS-PAGE, samples were transferred onto PVDF membrane (Invitrogen, USA), followed by incubation with primary antibodies. Then, proteins were treated with a
Relative expression of miR-139-5p

(a)

MCF7

NC mimics

miR-139-5p mimics

(b)

Time (h)

OD value (450 nm)

MCF7

NC mimics

miR-139-5p mimic

(c)

Wound healing percentage (%)

MDA-MB-231

NC mimics

miR-139-5p mimics

(d)

Invasion cells number

MDA-MB-231

NC mimics

miR-139-5p mimics

(e)

Apoptotic rate (%)

NC mimics

miR-139-5p mimics

(f)

Relative expression of miR-139-5p

MX-1

NC inhibitor

miR-139-5p inhibitor

(g)

OD value (450 nm)

Time (h)

NC inhibitor

miR-139-5p inhibitor

(h)

Wound healing percentage (%)

MX-1

NC inhibitor

miR-139-5p inhibitor

Figure 2: Continued.
secondary antibody (goat anti-rabbit IgG (1:2000, ab205718, Abcam, UK)) for 1 h. Protein levels were detected by the BeyoECL Chemiluminescence Kit (Beyotime Institute of Biotechnology). In this study, primary antibiotics were rabbit anti-MEX3A (1:500, ab79046, Abcam, UK) and rabbit anti-GAPDH (1:2500, ab9485, Abcam, UK).

2.6. CCK-8 Assay. Transfected cells were inoculated into a 96-well plate (2 × 10^3 cells/well). By using the CCK-8 kit, cell proliferation was assessed (Doidojo, Kumamoto, Japan) after cell cultivation. Optical density at 450 nm presented cell proliferative ability.

2.7. Cell Migration and Invasion Assays. Cells were placed in a 6-well plate (1 × 10^5 cells/well). When cells reached 100% confluence, a 10 μL pipette was used to create a scratch area in the central region of the monolayer cells. Then, cells were placed into a medium containing 1% FBS. At 0 h and 30 h, images of cell migration were taken and analyzed.

After cell transfection, MDA-MB-231 and MCF7 cells were suspended in a serum-free medium. Next, suspended cells were seeded to the upper side of the chamber (Corning Incorporated, Corning, NY, USA). The bottom side was injected the medium with 10% FBS. After cell incubation, invasive cells were treated with 4% formaldehyde solution and 0.25% crystal violet. Afterwards, cells were washed twice with PBS and air-dried. Number of invading cells was treated with 4% formaldehyde solution and double stained through using the PI-Annexin-V apoptosis detection kit (BD Biosciences, San Jose, CA, USA). Apoptosis status was analyzed by flow cytometry.

2.8. Cell Apoptosis Detection. Transfected cells were prepared and double stained through using the PI-Annexin-V apoptosis detection kit (BD Biosciences, San Jose, CA, USA). Apoptosis status was analyzed by flow cytometry (BD Biosciences, San Jose, CA, USA).

2.9. Dual-Luciferase Reporter Gene Detection. Wild-type (wt) and mutant-type (mut) sequences of MEX3A-3'UTR were subcloned into PGL3-M (Promega, Madison, WI, USA). MicroRNA-139-5p mimics or NC mimics were cotransfected into MDA-MB-231 cells with PGL3-3'UTR-wt or PGL3-MEX3A-3'UTR-mut. Luciferase activity was quantified using a dual-luciferase reporter gene system (Promega, USA).

2.10. Data Analysis. SPSS 22.0 (IBM Corp., Armonk, NY, USA) was used for data analysis. Data were presented in the form of mean ± standard deviation. t-test was introduced for two-group comparison. A statistically significant difference was considered when p value was less than 0.05.

3. Results

3.1. Significant Downregulation of MicroRNA-139-5p in BC. It is suggested by numerous studies that microRNA-139-5p is crucial in tumor progression [15, 16]. Hence, we attempted to illustrate functions of microRNA-139-5p in BC. TCGA-BRCA data indicated that the expression level of microRNA-139-5p in BC tissue was notably reduced (Figure 1(a)). Subsequent qRT-PCR result exhibited the same result (Figure 1(b)). MDA-MB-231 and MCF7 cells were used for cell functional assays later.

3.2. MicroRNA-139-5p Upregulation Suppresses Migration and Proliferation and Accelerates Apoptosis of BC Cells. Results of qRT-PCR displayed that transfected microRNA-139-5p mimics obviously elevated the expression level of microRNA-139-5p which was reduced notably by the microRNA-139-5p inhibitor (Figures 2(a) and 2(f)), which suggested that the transfection efficiency in each treatment group was great enough for subsequent experiments. As displayed in Figure 2(b) and Figure 2(g), microRNA-139-5p overexpression blocked BC cell proliferative ability; on the contrary, knockdown of microRNA-139-5p enhanced it. Then, we found through wound healing assay that microRNA-139-5p suppressed cell migration (Figures 2(c) and 2(h)). Similarly, Transwell results displayed that microRNA-139-5p had an inhibiting effect on the invasion of BC cells (Figures 2(d) and 2(i)). Finally, in order to determine whether cell apoptosis could be affected by microRNA-139-5p, a flow cytometry assay was used for apoptosis evaluation. The results indicated that the apoptosis rate of BC cells increased after transfection of microRNA-139-5p mimics and reduced after microRNA-139-5p inhibitor treatment (Figures 2(e) and 2(j)). It could draw a conclusion that microRNA-139-5p overexpression repressed the progression of BC cells and promoted apoptosis.

3.3. MEX3A Is a Target of MicroRNA-139-5p in BC. EdgeR differential analysis showed that 1,405 genes were upregulated and 757 were downregulated (Figure 3(a)). Then,
Survival analysis showed that the targeted binding sites of microRNA-139-5p (Figure 3(b)). 1,405 upregulated DEmRNAs to obtain 11 target genes with public databases. Predicted targets were intersected with targets of microRNA-139-5p were analyzed based on several binding sites of microRNA-139-5p and MEX3A; (i, j) MEX3A mRNA and protein expression levels. MEX3A is targeted by microRNA-139-5p in BC: (a) volcano map of DEmRNAs, red and green dots indicate up- and downregulated DEmRNAs, respectively; (b) Venn diagram of intersection of predicted targets of microRNA-139-5p and upregulated DEmRNAs; (c) Pearson correlation analysis of microRNA-139-5p and its predicted targets; (d) boxplot of MEX3A expression in the normal group (green) and the tumor group (red); (e) qRT-PCR was used to test mRNA expression of MEX3A in MCF-10A, MDA-MB-231, MCF7, HCC1937, and MX-1 cells; (f) Western blotting was used to measure MEX3A protein expression in each cell line; (g) dual-luciferase assay detection observed that (h) dual-luciferase detection was used to test whether microRNA-139-5p binds to MEX3A mRNA; (i, j) MEX3A mRNA and protein expression levels. *p < 0.05; **p < 0.0001.

Figure 3: MEX3A is targeted by microRNA-139-5p in BC: (a) volcano map of DEmRNAs, red and green dots indicate up- and downregulated DEmRNAs, respectively; (b) Venn diagram of intersection of predicted targets of microRNA-139-5p and upregulated DEmRNAs; (c) Pearson correlation analysis of microRNA-139-5p and its predicted targets; (d) boxplot of MEX3A expression in the normal group (green) and the tumor group (red); (e) qRT-PCR was used to test mRNA expression of MEX3A in MCF-10A, MDA-MB-231, MCF7, HCC1937, and MX-1 cells; (f) Western blotting was used to measure MEX3A protein expression in each cell line; (g) dual-luciferase assay detection observed that (h) dual-luciferase detection was used to test whether microRNA-139-5p binds to MEX3A mRNA; (i, j) MEX3A mRNA and protein expression levels. *p < 0.05; **p < 0.0001.

3.4. MicroRNA-139-5p Modulates Progression of BC Cells via MEX3A. To investigate whether MEX3A played a vital role in microRNA-139-5p suppressing BC, we studied MDA-MB-231 and MCF7 cell lines after transfection. qRT-PCR result exhibited that the upregulation of microRNA-139-5p targets of microRNA-139-5p were analyzed based on several public databases. Predicted targets were intersected with 1,405 upregulated DEmRNAs to obtain 11 target genes with targeted binding sites of microRNA-139-5p (Figure 3(b)). Survival analysis showed that the effect of target gene on survival time was not significant (Figure 52). The correlation analysis exhibited that the MEX3A presented the highest Pearson correlation coefficient with microRNA-139-5p and they were significantly negatively correlated (Figure 3(c)). Furthermore, MEX3A was noted to be significantly overexpressed in BC tissue (Figure 3(d)). At a cellular level, results of MEX3A were also prominently upregulated in BC cells (Figures 3(e) and 3(f)).

Binding sites of microRNA-139-5p on MEX3A mRNA were predicted by the TargetScan database (Figure 3(g)). Subsequently, dual-luciferase assay detection observed that luciferase activity of the wild-type group could be significantly reduced under overexpression of microRNA-139-5p, while no effects on luciferase activity could be observed in the mutant group; therefore, we confirmed that MEX3A could be one target of microRNA-139-5p (Figure 3(h)). Next, we detected the regulation of microRNA-139-5p on MEX3A expression and noted that the upregulation of microRNA-139-5p restrained the expression level of MEX3A at mRNA and protein manners (Figures 3(i) and 3(j)).
prominently reduced the mRNA level of MEX3A, while the mRNA level of MEX3A was restored after upregulating MEX3A (Figure 4(a)). Western blotting also showed the same trend in the protein expression of MEX3A as the results of qRT-PCR (Figure 4(b)). Then, the CCK-8 assay was carried out on cells in each transfection group, and it was noted that the upregulation of microRNA-139-5p inhibited cell proliferation, which was reversed partially by the upregulation of MEX3A (Figure 4(c)). Cell migration and invasion assays were employed to find that upregulating microRNA-139-5p could restrain BC cell growth. However, when MDA-MB-231 and MCF7 cells cotransfected with microRNA-139-5p mimics and oe-MEX3A, the migratory and invasive abilities were significantly elevated in comparison with cells only treated with microRNA-139-5p mimics (Figures 4(d) and 4(e)). Finally, microRNA-139-5p
overexpression elevated the apoptosis level of BC cells. However, the apoptosis level of BC cells with overexpressed microRNA-139-5p and MEX3A was significantly reduced (Figure 4(f)). These statistics indicated that MEX3A exerted a significant role in the inhibiting effect of microRNA-139-5p on BC progression.

4. Discussion

Multiple studies indicate that dysregulation of miRNAs is clinically linked with tumor growth and chemotherapy resistance, leading to high incidence and mortality in patients [17–19]. Previous literature has discovered that microRNA-139-5p is prominently lowly expressed in many cancers [20, 21]. Similarly, we noted that microRNA-139-5p was remarkably downregulated in BC. Through functional experiments, upregulated microRNA-139-5p performed a suppressive function in proliferation and migration and facilitate apoptosis of BC cells, which was the same as the results of Zhang et al. [22]. MicroRNA-139-5p can regulate the development of other cancers. For instance, microRNA-139-5p targets NOTCH1 to inhibit colorectal cancer cell proliferation and metastasis and promote apoptosis [23]. Combined with the above findings, we believe that microRNA-139-5p exerts tumor-suppression functions in BC.

MEX3 protein is crucial in self-renewal and differentiation and is also involved in the development of cancer cells. For instance, MEX3A expression in gastric cancer tissue is dramatically higher when it is compared with that in adjacent normal tissue, and knockout of hMEX-3A reduces the colony formation ability of gastric cancer cells as well as significantly affects the survival of cancer cells [24]. In colon cancer, MEX3A is involved in regulating colorectal epithelial homeostasis, injury response, and malignant transformation and is significantly upregulated [25]. In this study, we mainly explored its regulatory effect on BC cell functions. The results presented that MEX3A was overexpressed in BC and was significantly negatively correlated with microRNA-139-5p. We also noted that overexpression of microRNA-139-5p restrained the expression of MEX3A directly through binding to the 3′UTR of MEX3A. Moreover, functional analysis suggested that microRNA-139-5p and MEX3A overexpression attenuated the suppressive effect of overexpressing microRNA-139-5p alone on BC cell growth. On the above basis, we discovered that inhibition of microRNA-139-5p on BC cells was partially achieved by targeting MEX3A.

Our study demonstrated remarkable downregulation of microRNA-139-5p in BC, and abnormal expression of microRNA-139-5p inhibited malignant behaviors of BC cells by directly targeting MEX3A. Combined with our current results and previous findings, we proposed microRNA-139-5p regulates BC development as a tumor suppressor. This study enables us to further understand the mechanism of microRNA-139-5p in BC, which can develop new approaches for BC treatment. Although the experimental results in this paper are sufficient to prove the regulatory relationship between microRNA-139-5p and MEX3A, there are still some weaknesses. For instance, due to limited conditions, no clinical studies were conducted to further explore the influence of microRNA on the prognosis of patients in clinical practice, and no clinical tissue was utilized to further validate the relationship between microRNA-139-5p and MEX3A.

Data Availability

Data are available upon request from the corresponding author.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Supplementary Materials

Figure S1: transfection efficiency of microRNA-139-5p inhibitor and mimics. (a) Transfection efficiency was compared by qRT-PCR; (b) CCK-8 assay compares cell viability change between different treatment groups. Figure S2: GEPIA database analyzed OS for target genes. (Supplementary Materials)

References

[1] J. Ferlay, I. Soerjomataram, R. Dikshit et al., “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012,” International Journal of Cancer, vol. 136, no. 5, pp. E359–E386, 2015.
[2] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: a Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018.
[3] B. Xiu, Y. Chi, L. Liu et al., “LINC02273 drives breast cancer metastasis by epigenetically increasing AGR2 transcription,” Molecular Cancer, vol. 18, no. 1, p. 187, 2019.
[4] F. Xie, S. Hosany, S. Zhong et al., “MicroRNA-193a inhibits breast cancer proliferation and metastasis by downregulating WT1,” PLoS One, vol. 12, no. 10, article e0185565, 2017.
[5] D. P. Bartel, “MicroRNAs: target recognition and regulatory functions,” Cell, vol. 136, no. 2, pp. 215–233, 2009.
[6] Y. Lu, T. Qin, J. Li et al., “MicroRNA-140-5p inhibits invasion and angiogenesis through targeting VEGF-A in breast cancer,” Cancer Gene Therapy, vol. 24, no. 9, pp. 386–392, 2017.
[7] L. Lin, D. Liu, H. Liang, L. Xue, C. Su, and M. Liu, “MiR-1228 promotes breast cancer cell growth and metastasis through targeting SCAI protein,” International Journal of Clinical and Experimental Pathology, vol. 8, no. 6, pp. 6646–6655, 2015.
[8] B. Yang, W. Zhang, D. Sun et al., “Downregulation of miR-139-5p promotes prostate cancer progression through regulation of SOX5,” Biomedicine & Pharmacotherapy, vol. 109, pp. 2128–2135, 2019.
[9] H. Chen, H. Xu, Y. Meng, Y. Zhang, J. Chen, and X. Wei, “miR-139-5p regulates proliferation, apoptosis, and cell cycle of uterine leiomyoma cells by targeting TPD52,” Oncotargets and Therapy, vol. 9, pp. 6151–6160, 2016.
[10] J. Li, Q. Li, L. Lin et al., “Targeting the Notch1 oncogene by miR-139-5p inhibits glioma metastasis and epithelial-
mesenchymal transition (EMT),” *BMC Neurology*, vol. 18, no. 1, p. 133, 2018.

[11] B. Pereira, M. Le Borgne, N. T. Chartier, M. Billaud, and R. Almeida, “MEX-3 proteins: recent insights on novel post-transcriptional regulators,” *Trends in Biochemical Sciences*, vol. 38, no. 10, pp. 477–479, 2013.

[12] D. Yang, Y. Jiao, Y. Li, and X. Fang, “Clinical characteristics and prognostic value of MEX3A mRNA in liver cancer,” *PeerJ*, vol. 8, article e8252, 2020.

[13] Y. Huang, C. Fang, J. W. Shi, Y. Wen, and D. Liu, "Identification of hMex-3A and its effect on human bladder cancer cell proliferation,” *Oncotarget*, vol. 8, no. 37, pp. 61215–61225, 2017.

[14] A. C. V. Krepischi, M. Maschietto, E. N. Ferreira et al., "Genomic imbalances pinpoint potential oncogenes and tumor suppressors in Wilms tumors,” *Molecular Cytogenetics*, vol. 9, no. 1, 2016.

[15] K. Wang, J. Jin, T. Ma, and H. Zhai, "miR-139-5p inhibits the tumorigenesis and progression of oral squamous carcinoma cells by targeting HOXA9,” *Journal of Cellular and Molecular Medicine*, vol. 21, no. 12, pp. 3730–3740, 2017.

[16] J. Liu, C. Y. Li, Y. Jiang, Y. C. Wan, S. L. Zhou, and W. J. Cheng, "Tumor-suppressor role of miR-139-5p in endometrial cancer,” *Cancer Cell International*, vol. 18, no. 1, 2018.

[17] C. C. Nwaeburu, A. Abukiwan, Z. Zhao, and I. Herr, “Quercetin-induced miR-200b-3p regulates the mode of self-renewing divisions in pancreatic cancer,” *Molecular Cancer*, vol. 16, no. 1, 2017.

[18] R. Schreiber, R. Mezencev, L. V. Matyunina, and J. F. McDonald, “Evidence for the role of microRNA 374b in acquired cisplatin resistance in pancreatic cancer cells,” *Cancer Gene Therapy*, vol. 23, no. 8, pp. 241–245, 2016.

[19] H. Yan, Q. Li, J. Wu et al., "miR-629 promotes human pancreatic cancer progression by targeting FOXO3,” *Cell Death & Disease*, vol. 8, no. 10, article e3154, 2017.

[20] G. Qu and Y. Lin, "miR-139-5p inhibits epithelial-mesenchymal transition, migration and invasion of hepatocellular carcinoma cells by targeting ZEB1 and ZEB2,” *Biochemical and Biophysical Research Communications*, vol. 463, no. 3, pp. 315–321, 2015.

[21] R. Liu, M. Yang, Y. Meng et al., “Tumor-suppressive function of miR-139-5p in esophageal squamous cell carcinoma,” *PLoS One*, vol. 8, no. 10, article e77068, 2013.

[22] H. D. Zhang, D. W. Sun, L. Mao et al., "miR-139-5p inhibits the biological function of breast cancer cells by targeting Notch1 and mediates chemosensitivity to docetaxel,” *Biochemical and Biophysical Research Communications*, vol. 465, no. 4, pp. 702–713, 2015.

[23] L. Zhang, Y. Dong, N. Zhu et al., "MicroRNA-139-5p exerts tumor suppressor function by targeting NOTCH1 in colorectal cancer,” *Molecular cancer*, vol. 13, no. 1, 2014.

[24] H. Jiang, X. Zhang, J. Luo et al., "Knockdown of hMex-3A by small RNA interference suppresses cell proliferation and migration in human gastric cancer cells,” *Molecular Medicine Reports*, vol. 6, no. 3, pp. 575–580, 2012.

[25] P. Chatterji and A. K. Rustgi, "RNA binding proteins in intestinal epithelial biology and colorectal cancer,” *Trends in Molecular Medicine*, vol. 24, no. 5, pp. 490–506, 2018.